Papers by Emanuele Ferrero
Annals of Surgery, 2006
High rate of complications has been reported following revascularization for acute limb ischemia ... more High rate of complications has been reported following revascularization for acute limb ischemia (ALI). No adjuvant pharmacologic treatment, apart from anticoagulation and standard perioperative care, has been shown clinically effective. Aim of this study was to evaluate the effects of the prostacyclin analog iloprost as adjuvant to surgery for ALI. A total of 300 patients were randomly assigned to receive perioperative iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery), or placebo. The primary endpoint was the combined incidence of death and amputation at 3-month follow-up. Secondary endpoints were the incidence of each single major complication, total event rate, symptomatology, and tolerability. The combined incidence of death and amputation was 19.9% in the placebo and 14.1% in the iloprost group (relative risk, 1.56; 95% confidence interval, 0.89-2.75, P = 0.12, Cox regression analysis). A statistically significant lower mortality (4.7%) was reported in patients receiving iloprost, compared with controls (10.6%; relative risk, 2.61; 95% confidence interval, 1.07-6.37, P = 0.03). The overall incidence of fatal plus major cardiovascular events was 33.1% and 22.8% in placebo and iloprost groups, respectively (relative risk, 1.61; 95% confidence interval, 1.04-2.49, P = 0.03). No serious adverse reactions occurred after iloprost administration, nor differences in the incidence of bleeding or hypotension between treatment groups. Although at lower levels than previously reported, our results confirm the severity of ALI. Iloprost as adjuvant to surgery significantly reduced mortality and overall major event rate. Further data are needed to support this finding, and to face a still open medical issue.
European Journal of Vascular and Endovascular Surgery, 2013
Journal of Cardiology, 2014
Background: Stentless prostheses have an interesting hemodynamic performance when compared to ste... more Background: Stentless prostheses have an interesting hemodynamic performance when compared to stented prostheses and are recommended in cases of small aortic annulus. patients suffering from aortic disease, underwent aortic valve replacement. • Group A: 93 patients underwent stentless aortic valve implantation [stentless Biocor (Biocor Industria e Pesguisa Ltda, Belo Horizonte, Brazil) and stentless Sorin (Sorin Group, Saluggia, Italy)]. • Group B: 45 patients underwent stented aortic valve implantation (stented Biocor). Patients were assessed by clinical evaluation and echocardiography after a mean follow up of 124.5 ± 58.2 months.
A combined carotid endarterectomy (CEA) and cardiac procedure has higher early risk of stroke tha... more A combined carotid endarterectomy (CEA) and cardiac procedure has higher early risk of stroke than isolated CEA because of the widespread atherosclerosis in patients selected for simultaneous procedures. In this retrospective study, we review the results of combined coronary artery bypass grafting (CABG) and carotid endarterectomy (CEA) procedures. Materials and methods: Between January 2000 and December 2007, 91 patients with a mean age of 69.2+6.6 (24/67 female/male) underwent combined operations (CEA-CABG) on cardiopulmonary bypass (CPB) as elective surgery. The study population was divided, as follows: Group A: 83 patients (91.2%) had both venous and arterial revascularization; Group B: 8 patients (8.8%) had total arterial revascularization. CEA was performed in case of stenosis more than 80% and always before cardiac operation. These techniques were used: standard procedure (54.8%), eversion (39.2%), patch enlargement (6%). Immediately after the vascular procedure, CABGs were performed through median sternotomy. The mean EUROscore was 6.9+2.5%. Results: All neurological complications were in the group who underwent both venous and arterial revascularization (Group A), where a proximal anastomosis was made. All complications and deaths were in group A. Six patients had stroke (6.6%) and 2 had acute myocardial infarction (AMI) (2.2%). There were 8 in-hospital deaths (8.8%) and 1 late death (for stroke after five months). Conclusions: In our center, the incidence of stroke in simultaneous cardiovascular procedures was 5.5 times greater than in isolated cardiac or vascular procedures, which was probably related to the widespread vessels disease. An aortic cross clamp and surgical procedure on the ascending aorta are relevant risk factors for developing neurological events; much attention should be paid to aortic manipulation. In the sub-group who underwent total arterial revascularization with associated CEA procedures, we had no neurological events. A partial cross clamp and proximal anastomosis are relevant risk factors for developing neurological events. Therefore, in combined operations (CEA associated with CABG), it is probably more favourable performing a total arterial revascularization, avoiding partial ascending aortic clamping.
Annals of Vascular Surgery, 2015
The Nellix device (Endologix, Irvine, CA), has been designed with a brand new concept to seal the... more The Nellix device (Endologix, Irvine, CA), has been designed with a brand new concept to seal the abdominal aortic aneurysms, minimizing endoleaks and reducing reinterventions. We present the first open conversion of a Nellix endograft due to aortoduodenal fistula of a 74-year-old male patient treated for an abdominal aortic aneurysms of 62-mm diameter.
European Journal of Vascular and Endovascular Surgery, 2013
Annals of Vascular Surgery, 2014
A 59-year-old male, referred to our center with a ruptured aortic aneurysm, underwent urgent endo... more A 59-year-old male, referred to our center with a ruptured aortic aneurysm, underwent urgent endovascular repair and femoro-femoral crossover bypass. An endograft infection because of Aspergillus fumigatus occurred about 20 days after surgery. We removed the endograft and femoral prosthesis and we then performed an aorto-bi-iliac bypass with autogenous reversed superficial femoral veins. Five days after surgery, the patient died. Microbiological examination and postmortem examination showed the presence of A. fumigatus in femoral prosthesis, aortic wall, and periaortic exudate.
European Journal of Vascular and Endovascular Surgery, 2013
Annals of Vascular Surgery, 2015
We report a case of a metachronous common iliac artery and the internal iliac artery (IIA) aneury... more We report a case of a metachronous common iliac artery and the internal iliac artery (IIA) aneurysm developed 8 years after an aortobi-femoral bypass for treatment of abdominal aortic aneurysm associated at chronic occlusion of the right iliac axis. To exclude the metachronous aneurysm on the left iliac axis and to maintain the pelvic circulation, an external to IIA endografts were positioned ("U stent-graft technique"). At 6-month follow-up, the computed tomography scan showed patency of the endografts, of the bypass and of the IIA, without endoleak, or other adverse events.
Journal of vascular surgery, 2015
We compared the outcomes and the durability of endovascular recanalization (EVR) with the Viabahn... more We compared the outcomes and the durability of endovascular recanalization (EVR) with the Viabahn (W. L. Gore and Associates, Flagstaff, Ariz) covered stent graft vs traditional aortobifemoral or aortofemoral bypass grafting for complex aortoiliac occlusions. Between 2008 and 2014, 11 unilateral iliac occlusions and 11 aortobiiliac occlusions were treated by EVR. Also collected were data from the last 21 consecutive patients treated in the same period by aortofemoral (n = 6) or aortobifemoral (n = 15) bypass grafting. In accordance with the TransAtlantic Inter-Society Consensus II (TASC II) document, only patients with type D lesions were considered. Kaplan-Meier estimates for patency were calculated, and Cox proportional hazard modeling was performed. The difference in risk factors between the groups was not significant. General anesthesia was required in 100% of the surgical group, and local or locoregional anesthesia was used for EVR. Suprarenal aortic cross-clamping was required...
Journal of Vascular Surgery, 2015
We compared the outcomes and the durability of endovascular recanalization (EVR) with the Viabahn... more We compared the outcomes and the durability of endovascular recanalization (EVR) with the Viabahn (W. L. Gore and Associates, Flagstaff, Ariz) covered stent graft vs traditional aortobifemoral or aortofemoral bypass grafting for complex aortoiliac occlusions. Between 2008 and 2014, 11 unilateral iliac occlusions and 11 aortobiiliac occlusions were treated by EVR. Also collected were data from the last 21 consecutive patients treated in the same period by aortofemoral (n = 6) or aortobifemoral (n = 15) bypass grafting. In accordance with the TransAtlantic Inter-Society Consensus II (TASC II) document, only patients with type D lesions were considered. Kaplan-Meier estimates for patency were calculated, and Cox proportional hazard modeling was performed. The difference in risk factors between the groups was not significant. General anesthesia was required in 100% of the surgical group, and local or locoregional anesthesia was used for EVR. Suprarenal aortic cross-clamping was required in nine of the open surgical procedures (41%). A brachial percutaneous approach was performed in all patients undergoing EVR, and technical success was 100% in both groups. All of the attempts at EVR were successful. At the 2-year follow-up, primary patency did not differ significantly between the endovascular (91%) and surgical (95%) groups. This was seen in the univariate model (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.02-2.95; P = .28) and in the multivariate model (HR, 0.77; 95% CI, 0.06-10.07; P = .84) for group (HR, 0.58; 95% CI, 0.04-7.72; P = .68), age (HR, 0.89; 95% CI, 0.73-1.08; P = .24), symptoms (HR, 1.98; 95% CI, 0.42-9.46; P = .39), and occlusion (HR, 3.22; 95% CI, 0.51-20.35; P = .21). The average hospital length of stay was shorter for patients treated with ERV than for those treated with open surgery (3.9 ± 2.2 vs 5.8 ± 3.1 days, respectively; P = .03). The complication rate was 4% for EVR vs 18% in the surgical group (P = .32). At 2 years of follow-up, the results of endoluminal bypass grafting with the Viabahn stent to treat complex aortoiliac disease are promising. Longer-term results are needed to fully evaluate the potential benefits and longer-term patency.
BACKGROUND: Large randomized controlled trials have shown that carotid endarterectomy (CEA) is be... more BACKGROUND: Large randomized controlled trials have shown that carotid endarterectomy (CEA) is beneficial in the treatment of recent severe symptomatic carotid stenosis. Data are lacking concerning the risks of early CEA (<48 hours) for stroke in evolution (SIE) or crescendo transient ischemic attack (CTIA). The primary end point of this retrospective study was to evaluate the incidence of stroke, major adverse cardiac events (MACEs), and death within the first 30 days after early CEA performed within 48 hours in patients presenting with transient ischemic attack (TIA)/SIE.
METHODS: Between 2001 and 2010, we treated 3,023 carotid artery stenoses, 29.5% (891/3,021) of which were in symptomatic patients. Early CEA within 48 hours after acute TIA/SIE was performed in 176 patients. Patients were divided into 3 groups for analysis of outcome after early CEA in symptomatic patients according to their initial neurologic deficit. Group 1 included 55 patients with TIA (single); group 2 included 55 patients with CTIA, and group 3 included 66 patients with SIE. Carotid artery stenosis was evaluated by duplex ultrasonography (DS). All patients were pre- and postoperatively visited by an experienced consultant neurologist who evaluated the neurologic status according to the modified Rankin Scale and the National Institutes of Health Stroke Scale (NIHSS). At admission, surgery was not performed on patients with disabling neurologic deficit (NIHSS score: >6) except for 4 selected cases (NIHSS score range: 8-14), patients with cerebral lesions >3 cm in diameter, patients with the presence or suspicion of parenchymal hemorrhage, patients with occlusion of the middle cerebral artery, and those who were deemed unfit for surgery. Clinical and DS follow-up examinations were performed after 6 and 12 months and annually thereafter. The mean duration of follow-up was 29.4 months (range: 0-120 months).
RESULTS: The cumulative TIA/stroke/myocardial infarction/death rate at 30 days was 3.9% (7/176). TIA and stroke rates were 0% (0/176) and 3.4% (6/176), respectively. The stroke rate in groups 1, 2, and 3 was 1.8% (1/55), 0% (0/55), and 7.6% (5/66), respectively. No hemorrhagic strokes, TIAs, or MACEs were detected after surgery. Stroke risk was higher in group 3 than in groups 1 or 2, but the differences in the 3 groups were not statistically significant (group 1 vs. group 2: 1/55 vs. 0/55 events [P = 0.3151]); group 1 vs. group 3: 1/55 vs. 5/66 events [P = 0.3020]; and group 2 vs. group 3: 0/55 vs. 5/66 events [P = 0.1039]. Thirty-day follow-up was available for all patients, while long-term follow-up (mean: 32.7 ± 26.8 months) was available only for 158 patients (1 patient died and 17 were lost to follow-up).
CONCLUSIONS: CEA can be performed with an acceptable risk in properly selected symptomatic patients within 48 hours after TIA or SIE. The benefits of early CEA in symptomatic patients include the prevention of recurrent stroke.
European Journal of Vascular and Endovascular Surgery
OBJECTIVES: ACST-2 is currently the largest trial ever conducted to compare carotid artery stenti... more OBJECTIVES: ACST-2 is currently the largest trial ever conducted to compare carotid artery stenting (CAS) with carotid endarterectomy (CEA) in patients with severe asymptomatic carotid stenosis requiring revascularization. METHODS: Patients are entered into ACST-2 when revascularization is felt to be clearly indicated, when CEA and CAS are both possible, but where there is substantial uncertainty as to which is most appropriate. Trial surgeons and interventionalists are expected to use their usual techniques and CE-approved devices. We report baseline characteristics and blinded combined interim results for 30-day mortality and major morbidity for 986 patients in the ongoing trial up to September 2012. RESULTS: A total of 986 patients (687 men, 299 women), mean age 68.7 years (SD ± 8.1) were randomized equally to CEA or CAS. Most (96%) had ipsilateral stenosis of 70-99% (median 80%) with contralateral stenoses of 50-99% in 30% and contralateral occlusion in 8%. Patients were on appr...
Annals of Surgery, 2006
High rate of complications has been reported following revascularization for acute limb ischemia ... more High rate of complications has been reported following revascularization for acute limb ischemia (ALI). No adjuvant pharmacologic treatment, apart from anticoagulation and standard perioperative care, has been shown clinically effective. Aim of this study was to evaluate the effects of the prostacyclin analog iloprost as adjuvant to surgery for ALI. A total of 300 patients were randomly assigned to receive perioperative iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery), or placebo. The primary endpoint was the combined incidence of death and amputation at 3-month follow-up. Secondary endpoints were the incidence of each single major complication, total event rate, symptomatology, and tolerability. The combined incidence of death and amputation was 19.9% in the placebo and 14.1% in the iloprost group (relative risk, 1.56; 95% confidence interval, 0.89-2.75, P = 0.12, Cox regression analysis). A statistically significant lower mortality (4.7%) was reported in patients receiving iloprost, compared with controls (10.6%; relative risk, 2.61; 95% confidence interval, 1.07-6.37, P = 0.03). The overall incidence of fatal plus major cardiovascular events was 33.1% and 22.8% in placebo and iloprost groups, respectively (relative risk, 1.61; 95% confidence interval, 1.04-2.49, P = 0.03). No serious adverse reactions occurred after iloprost administration, nor differences in the incidence of bleeding or hypotension between treatment groups. Although at lower levels than previously reported, our results confirm the severity of ALI. Iloprost as adjuvant to surgery significantly reduced mortality and overall major event rate. Further data are needed to support this finding, and to face a still open medical issue.
European Journal of Vascular and Endovascular Surgery, 2007
Objectives. To evaluate the effects of iloprost, in addition to surgery, on the outcome of acute ... more Objectives. To evaluate the effects of iloprost, in addition to surgery, on the outcome of acute lower limb ischemia (ALLI). Design. Post-hoc analysis of a randomized, double-blind, placebo-controlled study. Methods. In the context of the ILAILL (ILoprost in Acute Ischemia of Lower Limbs) study, 192 elderly patients (>70 years old) undergoing surgery for ALLI were assigned to receive perioperative iloprost (intra-arterial, intra-operative bolus of 3000 ng, plus intravenous infusion of 0.5e2.0 ng/kg/min for six hours/day for 4e7 days following surgery), or placebo (iloprost: n ¼ 100; placebo: n ¼ 92). Patients were followed-up for three-months following surgical revascularization. Results. The combined incidence of death and amputation (primary study end-point) was significantly reduced in patients treated with iloprost (16.0% vs 27.2% in the placebo group; hazard ratio 1.99, 95% confidence interval 1.05e3.75, p ¼ 0.03). A statistically significant lower mortality (6.0%) was reported in patients receiving iloprost, compared to controls (15.2%) (hazard ratio 2.93, 1.11e7.71, p ¼ 0.03). The overall incidence of death and major cardiovascular events was lower in patients receiving iloprost compared to those assigned placebo (24.0% and 35.9%, respectively), at the limits of statistical significance (relative risk 1.64, 0.97e2.79, p ¼ 0.06). Conclusions. These results confirm the poor outcome in elderly patients with ALLI. Based on a subgroup analysis iloprost, as an adjuvant to surgery, appears to reduce the combined end-point of death and amputation.
A combined carotid endarterectomy (CEA) and cardiac procedure has higher early risk of stroke tha... more A combined carotid endarterectomy (CEA) and cardiac procedure has higher early risk of stroke than isolated CEA because of the widespread atherosclerosis in patients selected for simultaneous procedures. In this retrospective study, we review the results of combined coronary artery bypass grafting (CABG) and carotid endarterectomy (CEA) procedures. Materials and methods: Between January 2000 and December 2007, 91 patients with a mean age of 69.2+6.6 (24/67 female/male) underwent combined operations (CEA-CABG) on cardiopulmonary bypass (CPB) as elective surgery. The study population was divided, as follows: Group A: 83 patients (91.2%) had both venous and arterial revascularization; Group B: 8 patients (8.8%) had total arterial revascularization. CEA was performed in case of stenosis more than 80% and always before cardiac operation. These techniques were used: standard procedure (54.8%), eversion (39.2%), patch enlargement (6%). Immediately after the vascular procedure, CABGs were performed through median sternotomy. The mean EUROscore was 6.9+2.5%. Results: All neurological complications were in the group who underwent both venous and arterial revascularization (Group A), where a proximal anastomosis was made. All complications and deaths were in group A. Six patients had stroke (6.6%) and 2 had acute myocardial infarction (AMI) (2.2%). There were 8 in-hospital deaths (8.8%) and 1 late death (for stroke after five months). Conclusions: In our center, the incidence of stroke in simultaneous cardiovascular procedures was 5.5 times greater than in isolated cardiac or vascular procedures, which was probably related to the widespread vessels disease. An aortic cross clamp and surgical procedure on the ascending aorta are relevant risk factors for developing neurological events; much attention should be paid to aortic manipulation. In the sub-group who underwent total arterial revascularization with associated CEA procedures, we had no neurological events. A partial cross clamp and proximal anastomosis are relevant risk factors for developing neurological events. Therefore, in combined operations (CEA associated with CABG), it is probably more favourable performing a total arterial revascularization, avoiding partial ascending aortic clamping.
Nota: si segnala che gli Impact Factor attribuiti alle pubblicazioni sono quelli pubblicati in ba... more Nota: si segnala che gli Impact Factor attribuiti alle pubblicazioni sono quelli pubblicati in banca dati ISI Journal Citation Report e relativi al 2007, ultima annata disponibile al momento della compilazione della Relazione.
Uploads
Papers by Emanuele Ferrero
METHODS: Between 2001 and 2010, we treated 3,023 carotid artery stenoses, 29.5% (891/3,021) of which were in symptomatic patients. Early CEA within 48 hours after acute TIA/SIE was performed in 176 patients. Patients were divided into 3 groups for analysis of outcome after early CEA in symptomatic patients according to their initial neurologic deficit. Group 1 included 55 patients with TIA (single); group 2 included 55 patients with CTIA, and group 3 included 66 patients with SIE. Carotid artery stenosis was evaluated by duplex ultrasonography (DS). All patients were pre- and postoperatively visited by an experienced consultant neurologist who evaluated the neurologic status according to the modified Rankin Scale and the National Institutes of Health Stroke Scale (NIHSS). At admission, surgery was not performed on patients with disabling neurologic deficit (NIHSS score: >6) except for 4 selected cases (NIHSS score range: 8-14), patients with cerebral lesions >3 cm in diameter, patients with the presence or suspicion of parenchymal hemorrhage, patients with occlusion of the middle cerebral artery, and those who were deemed unfit for surgery. Clinical and DS follow-up examinations were performed after 6 and 12 months and annually thereafter. The mean duration of follow-up was 29.4 months (range: 0-120 months).
RESULTS: The cumulative TIA/stroke/myocardial infarction/death rate at 30 days was 3.9% (7/176). TIA and stroke rates were 0% (0/176) and 3.4% (6/176), respectively. The stroke rate in groups 1, 2, and 3 was 1.8% (1/55), 0% (0/55), and 7.6% (5/66), respectively. No hemorrhagic strokes, TIAs, or MACEs were detected after surgery. Stroke risk was higher in group 3 than in groups 1 or 2, but the differences in the 3 groups were not statistically significant (group 1 vs. group 2: 1/55 vs. 0/55 events [P = 0.3151]); group 1 vs. group 3: 1/55 vs. 5/66 events [P = 0.3020]; and group 2 vs. group 3: 0/55 vs. 5/66 events [P = 0.1039]. Thirty-day follow-up was available for all patients, while long-term follow-up (mean: 32.7 ± 26.8 months) was available only for 158 patients (1 patient died and 17 were lost to follow-up).
CONCLUSIONS: CEA can be performed with an acceptable risk in properly selected symptomatic patients within 48 hours after TIA or SIE. The benefits of early CEA in symptomatic patients include the prevention of recurrent stroke.
METHODS: Between 2001 and 2010, we treated 3,023 carotid artery stenoses, 29.5% (891/3,021) of which were in symptomatic patients. Early CEA within 48 hours after acute TIA/SIE was performed in 176 patients. Patients were divided into 3 groups for analysis of outcome after early CEA in symptomatic patients according to their initial neurologic deficit. Group 1 included 55 patients with TIA (single); group 2 included 55 patients with CTIA, and group 3 included 66 patients with SIE. Carotid artery stenosis was evaluated by duplex ultrasonography (DS). All patients were pre- and postoperatively visited by an experienced consultant neurologist who evaluated the neurologic status according to the modified Rankin Scale and the National Institutes of Health Stroke Scale (NIHSS). At admission, surgery was not performed on patients with disabling neurologic deficit (NIHSS score: >6) except for 4 selected cases (NIHSS score range: 8-14), patients with cerebral lesions >3 cm in diameter, patients with the presence or suspicion of parenchymal hemorrhage, patients with occlusion of the middle cerebral artery, and those who were deemed unfit for surgery. Clinical and DS follow-up examinations were performed after 6 and 12 months and annually thereafter. The mean duration of follow-up was 29.4 months (range: 0-120 months).
RESULTS: The cumulative TIA/stroke/myocardial infarction/death rate at 30 days was 3.9% (7/176). TIA and stroke rates were 0% (0/176) and 3.4% (6/176), respectively. The stroke rate in groups 1, 2, and 3 was 1.8% (1/55), 0% (0/55), and 7.6% (5/66), respectively. No hemorrhagic strokes, TIAs, or MACEs were detected after surgery. Stroke risk was higher in group 3 than in groups 1 or 2, but the differences in the 3 groups were not statistically significant (group 1 vs. group 2: 1/55 vs. 0/55 events [P = 0.3151]); group 1 vs. group 3: 1/55 vs. 5/66 events [P = 0.3020]; and group 2 vs. group 3: 0/55 vs. 5/66 events [P = 0.1039]. Thirty-day follow-up was available for all patients, while long-term follow-up (mean: 32.7 ± 26.8 months) was available only for 158 patients (1 patient died and 17 were lost to follow-up).
CONCLUSIONS: CEA can be performed with an acceptable risk in properly selected symptomatic patients within 48 hours after TIA or SIE. The benefits of early CEA in symptomatic patients include the prevention of recurrent stroke.